The archive · Health & Care · Strategic decision · 2019–2026
Signos bets FDA's OTC CGM category opens consumer weight loss; $20M Series B
Metabolic health app pairing CGM with AI coaching; rode Dexcom Stelo's 2024 OTC clearance and won its own OTC CGM clearance (2025).
Signos
What the business is
Signos sells a metabolic health subscription: members wear a continuous glucose monitor (Dexcom Stelo OTC), log food and exercise in the app, and get real-time AI recommendations on how their body responds — aimed at weight management, not just diabetes care.
Starting capital：$20M Series B (Oct 2023) led by Cheyenne Ventures and GV, joined by Dexcom Ventures and Samsung (TechCrunch).
How it started
Founded in 2019 in San Francisco by Sharam Fouladgar-Mercer, Signos started as a prescription-based metabolic platform pairing CGM data with an AI coaching engine. Fouladgar-Mercer, who struggled with weight since childhood, positioned CGM as a lifestyle tool for people without diabetes — TechCrunch cites more than 96 million Americans with prediabetes as the market.
What happened
In Oct 2023 Signos raised a $20M Series B from Cheyenne Ventures and GV, with Dexcom Ventures and Samsung on board (TechCrunch). When FDA cleared Dexcom Stelo as the first over-the-counter glucose biosensor in March 2024, Signos integrated it, removing the prescription barrier from its funnel. In Aug 2025 FDA cleared Signos' own OTC Glucose Monitoring System — the Stelo sensor plus Signos' AI — for weight management, the first such clearance, and Signos launched it to consumers and employers.
How it ended up
Still operating: selling the OTC program directly to consumers and through employers and health plans, positioned to work alongside GLP-1 programs; no exit announced.
Background
Signos was founded in San Francisco in 2019 by Sharam Fouladgar-Mercer as a metabolic health platform: a continuous glucose monitor paired with an AI engine that learns how an individual's body responds to food and exercise, aimed at weight management rather than just diabetes care. TechCrunch framed the market as the 96M+ Americans with prediabetes.
The regulatory opening arrived in two steps. In Oct 2023 Signos raised a $20M Series B led by Cheyenne Ventures and GV with Dexcom Ventures and Samsung participating. Then in March 2024 the FDA cleared Dexcom Stelo as the first glucose biosensor sold without a prescription, and Signos integrated it — no doctor visit needed to start the program. In Aug 2025 the FDA cleared Signos' own OTC Glucose Monitoring System (Stelo sensor plus Signos AI) for weight management, the first clearance of its kind, and the company launched it to consumers and employers.
Signos now sells the OTC subscription directly and to employers and health plans, framing itself as a non-pharmacological option that can run alongside GLP-1 programs. As of Sept 2026 it remains private and live; membership and revenue figures are not public.
What has to be true
- The OTC clearance removed the prescription and doctor visit — the biggest friction in Signos' consumer funnel (Dexcom press release; HIT Consultant).
- Signos had the software layer ready when the hardware category opened: AI engine, employer program and research built before the Stelo clearance (TechCrunch).
- Strategic investors wired it into the category: Dexcom Ventures and Samsung joined the Series B alongside GV (TechCrunch).
- The follow-on FDA clearance in Aug 2025 converted a partner-driven position into an owned regulatory position (HIT Consultant).
What can be applied
Ride someone else's regulatory breakthrough: Signos didn't build the sensor — it bet on Dexcom's OTC clearance, stacked its AI on top, then won its own clearance once the category existed.
Aftermath
As of 2026-09-02 Signos is still private and live: it sells the OTC Signos Glucose Monitoring System to consumers and rolls it out to employers and health plans, positioned to complement GLP-1 weight-loss programs. Its bet now depends on the OTC CGM category scaling beyond early adopters, and on consumers paying for the subscription layer; no revenue or membership figures are public.
Sources
- Signos raises $20M to sprinkle AI fairy dust on the weight-loss industry
- Stelo by Dexcom First Glucose Biosensor Cleared by FDA as Over-the-Counter
- Signos Launches First FDA-Cleared Glucose Monitoring System for Weight Management
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card